Keyword: Becton Dickinson
While most of 2024’s 10 largest medtech companies are projected to hold steady in their positions, BD is set to break from the pack in the coming years—leapfrogging three companies to take a spot in the top five, after its late-2017 acquisition of C.R. Bard.
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and reap billions in additional sales in new market segments.
Gilead's top executives step down, Amgen's R&D head leaves for the startup scene, and BMS' commercial chief jumps ship.
Clinical Innovations has hired Richard Ji, BD’s VP of catheter solutions, to lead its operations and streamline the company as it looks to expand.
Stryker has offered to acquire its rival, Boston Scientific, in what would be one of the largest medical device deals on record, according to reports.
Medical device maker Becton Dickinson is suing rival Cytek Biosciences and a group of former employees, claiming they stole trade secrets.
Inspectors identify violations at the Becton Dickinson site in New Jersey but allow tubes at the center of the investigation to stay on the market.
C.R. Bard scored FDA approval for its Lutonix drug-coated balloon to treat a complication of end-stage renal disease.
Between its $12 billion deal to acquire CareFusion in 2014 and a $24 billion deal to buy C.R. Bard, Becton Dickinson made some key offloads and is investing $100 million in its Nebraska plant to boost its insulin syringe manufacturing.
After acquiring just two companies—a pair of hospital bed makers—in 2015, Stryker made up for lost time in 2016. The company kicked off an acquisitive year by making three deals in February. But it isn’t just relying on M&A.